Company intelligence / Profile preview
Forte Biosciences, Inc.
Dallas, Texas, United Statesfortebiorx.com ↗
- Ownership
- Public · FBRX
- Employees
- ~14
- Development stage
- Other
01
Overview
Forte Biosciences has completed a Phase 1 healthy volunteer SAD/MAD study for FB102 which demonstrated a good safety profile. The company is currently conducting a celiac disease patient trial with nearly half of patients having completed both FB102 dosing and gluten challenge. FB102 continues to be well-tolerated with no dropouts to date. Topline results are expected in Q2 2025. A vitiligo trial is also expected to begin shortly.[3][6]
- Therapeutic areas
- GastroenterologyImmunologyDermatology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
National Institutes of HealthNational Institute of Allergy and Infectious Diseases[8]
Beyond the preview
Go deeper on Forte Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forte Biosciences, Inc..